Dougherty's Pharmacy, Inc. (MYDP) Financial Statements (2024 and earlier)

Company Profile

Business Address 5924 ROYAL LANE, SUITE 250
DALLAS, TX 75230
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 5912 - Drug Stores and Proprietary Stores (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2019
MRQ
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 24886
Cash and cash equivalents 24886
Receivables 1,6882,184
Inventory, net of allowances, customer advances and progress billings 2,6893,562
Inventory 2,6893,562
Prepaid expense 277267
Other undisclosed current assets  143
Total current assets: 4,9026,242
Noncurrent Assets
Property, plant and equipment 8881,045
Long-term investments and receivables, including: 451448
Other undisclosed long-term investments and receivables 451448
Intangible assets, net (including goodwill) 2,2212,892
Intangible assets, net (excluding goodwill) 2,2212,892
Other undisclosed noncurrent assets  2,000
Total noncurrent assets: 3,5606,385
TOTAL ASSETS: 8,46212,627
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 3,4263,552
Accounts payable 3,1333,123
Accrued liabilities 293429
Debt 4,8424,644
Total current liabilities: 8,2688,196
Noncurrent Liabilities
Long-term debt and lease obligation 2,0962,801
Long-term debt, excluding current maturities 2,0962,801
Total noncurrent liabilities: 2,0962,801
Total liabilities: 10,36410,997
Equity
Equity, attributable to parent (1,902)1,630
Common stock 22
Treasury stock, value (397)(397)
Additional paid in capital 60,21760,221
Accumulated deficit (61,724)(58,196)
Total equity: (1,902)1,630
TOTAL LIABILITIES AND EQUITY: 8,46212,627

Income Statement (P&L) ($ in thousands)

3/31/2019
TTM
12/31/2018
12/31/2017
Revenues 36,05140,213
Cost of revenue (26,926)(29,390)
Gross profit: 9,12510,823
Operating expenses (10,188)(11,403)
Operating loss: (1,063)(580)
Interest and debt expense (439)(427)
Loss from continuing operations before equity method investments, income taxes: (1,502)(1,007)
Other undisclosed income (loss) from continuing operations before income taxes 2(72)
Loss from continuing operations before income taxes: (1,500)(1,079)
Income tax expense (2,028)(1,029)
Loss from continuing operations: (3,528)(2,108)
Loss before gain (loss) on sale of properties: (3,528)(2,108)
Net loss available to common stockholders, diluted: (3,528)(2,108)

Comprehensive Income ($ in thousands)

3/31/2019
TTM
12/31/2018
12/31/2017
Net loss: (3,528)(2,108)
Comprehensive loss, net of tax, attributable to parent: (3,528)(2,108)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: